Article

Bausch & Lomb gains license to plasmin technology

Talecris Biotherapeutics granted Bausch & Lomb the exclusive license to recombinant plasmin technology for use in ophthalmology. Bausch & Lomb and Talecris Biotherapeutics co-developed rPlasmin, a recombinant derivative of the human blood component plasmin. The enzyme degrades many blood plasma proteins, including fibrin clots.

Talecris Biotherapeutics granted Bausch & Lomb the exclusive license to recombinant plasmin technology for use in ophthalmology. Bausch & Lomb and Talecris Biotherapeutics co-developed rPlasmin, a recombinant derivative of the human blood component plasmin. The enzyme degrades many blood plasma proteins, including fibrin clots.

“Plasmin technology has the potential to treat multiple conditions for which vitrectomy surgery now is used,” said Praveen Tyle, PhD, Bausch & Lomb’s chief scientific officer and senior vice president of Global Research and Development. “We are already developing plasma-derived plasmin for ocular indications. This agreement is significant because it gives us the opportunity to develop a next-generation recombinant version with the potential to reach more global markets.”

Bausch & Lomb is enrolling patients in early-stage clinical trials to evaluate plasmin’s therapeutic potential to relieve retinal traction.

Under the terms of the agreement, the company will make milestone payments based on the development and registration progress as well as pay ongoing royalties based on product sales.

In other news, Bausch & Lomb will be eliminating about 400 positions over the next several months. The majority of cuts will be made to temporary jobs in manufacturing plants in Waterford, Ireland; Livingston, Scotland; and Rochester, NY.

The company said the temporary workforce will be adjusted to meet changing business conditions and expects to rehire some of the temporary employees in the new year.

Bausch & Lomb is also transitioning its contact lens lines to newer designs made using more automated, advanced manufacturing technology.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.